Mark A. Velleca
2020 - G1 Therapeutics
In 2020, Mark A. Velleca earned a total compensation of $4M as Former Chief Executive Officer and President at G1 Therapeutics, which was about the same as previous year.
Compensation breakdown
Non-Equity Incentive Plan | $305,000 |
---|---|
Option Awards | $3,069,704 |
Salary | $608,308 |
Other | $8,550 |
Total | $3,991,562 |
Velleca received $3.1M in option awards, accounting for 77% of the total pay in 2020.
Velleca also received $305K in non-equity incentive plan, $608.3K in salary and $8.6K in other compensation.
Rankings
In 2020, Mark A. Velleca's compensation ranked 2,858th out of 13,090 executives tracked by ExecPay. In other words, Velleca earned more than 78.2% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,858 | 78th |
Manufacturing | 1,101 | 80th |
Chemicals And Allied Products | 406 | 82nd |
Drugs | 350 | 82nd |
Pharmaceutical Preparations | 256 | 83rd |
Velleca's colleagues
We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2020.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019